Introduction {#s1}
============

N-type (Cav2.2) calcium channels are present in the presynaptic nerve terminals of many neurons ([@bib101]), where they play a major role in synaptic transmission. In particular, N-type channels in primary sensory neurons play a major role in pain/nociceptive signaling ([@bib73]; [@bib41]; [@bib83]; [@bib90]) and they are therefore an attractive target for inhibiting pain. In fact, one of the few new treatments for pain introduced in the last 50 years is intrathecal application of ziconotide, a highly potent peptide blocker of N-type calcium channels ([@bib35]). While validating N-type calcium channels as a promising pharmacological target for treating pain, ziconotide has many practical drawbacks, as it is a large peptide with three disulfide bridges that is expensive to synthesize and must be administered intrathecally. Therefore, development of small molecule N-type blockers is an attractive strategy being actively pursued (reviewed by [@bib53]; [@bib109]; [@bib110]; [@bib75]; [@bib107]).

Compared to the pharmacology of L-type (Cav1) calcium channels, which has been explored for many years, the pharmacology of N-type channels is still at an early stage. A number of L-type calcium channel inhibitors, including nifedipine, verapamil, and diltiazem, are widely-used clinically for treating arrhythmia and hypertension. The binding sites for the major classes of L-type calcium channel blockers have been defined (reviewed by [@bib19]; [@bib96]) and the characteristics of inhibition have been studied in detail. In contrast, while the binding sites for peptide toxin inhibitors of N-type channels have been defined ([@bib31]; [@bib109]; [@bib13]), there is no such knowledge for small molecule inhibitors of N-type channels. In fact, most have been described based on screens that provide only minimal characterization of how they interact with channel gating or permeation.

There are general features that appear to be shared by many small-molecule inhibitors of voltage-dependent sodium and calcium channels. The canonical small-molecule inhibitors of voltage-gated channels are local anesthetics like lidocaine, which inhibit voltage-dependent sodium channels by a mechanism that involves tight binding to open and inactivated states of the channel, with relatively weak binding to the closed resting state of the channel ([@bib44]). This property results in channel inhibition that is promoted by steady depolarization (voltage-dependent inhibition) or by repeated cycling through the open state (use-dependence), which occurs if the recovery from depolarization-induced binding is slow enough. Most small-molecule inhibitors of calcium channels also show voltage-dependent inhibition. This behavior is characteristic of inhibition of L-type channels by nifedipine, diltiazem, and verapamil ([@bib19]) and has also been described for many small molecule inhibitors of N-type calcium channels ([@bib109]; [@bib110]).

A particularly interesting feature of local anesthetic inhibition of sodium channels was revealed by studies of permanently charged cationic derivatives of the molecules, notably QX-314 (N-ethyl-lidocaine). QX-314 is ineffective in blocking neuronal sodium channels if applied externally ([@bib33]), apparently because it is too large to enter the outer mouth of the channel, but blocks effectively when applied to the internal (cytoplasmic) face of the channel, presumably because the inner mouth is larger. With intracellular application, QX-314 blocks sodium channels in a highly use-dependent manner because it enters channels only when the channels are open and is trapped inside channels when drug-occupied channels close ([@bib92]; [@bib106]; [@bib18]). The inability of QX-314 to inhibit from the outside of the cell can be exploited to selectively block excitability of nociceptor neurons expressing channels like TRPV1 and TRPA1, whose pores are large enough to pass the QX-314 cation into the cell, effectively silencing only these neurons and producing a selective elimination of pain or itch by blocking action potential conduction to the CNS ([@bib10]; [@bib82]; [@bib77]).

Spurred by the relative lack of knowledge about the pharmacology of N-type channel blockers and by the possibility of pursuing a strategy of large-pore channel-mediated drug entry to selectively block transmitter release from nociceptors, we explored the channel blocking properties of a cationic N-type channel inhibitor based on a scaffold described for a group of neutral N-type channel blockers ([@bib84]). Surprisingly, we found that the cationic molecule effectively inhibits Cav2.2 channels when administered externally, as well as internally, and actually acts more rapidly with external application. Even more surprisingly, we found that the compound also very effectively inhibits both tetrodotoxin-sensitive and tetrodotoxin-resistant voltage-gated sodium channels with external application, producing use-dependent sodium channel inhibition more potently than lidocaine or bupivacaine. In in vivo tests, the cationic molecule was highly effective in producing long-lasting analgesia in mouse models of surgical and inflammatory pain and was also very effective in reducing lung inflammation in an ovalbumin-sensitization model of allergic airway disease.

Results {#s2}
=======

Voltage-dependent inhibition of Cav2.2 channels by neutral NNCB-2 {#s2-1}
-----------------------------------------------------------------

Our strategy was to design a neutral compound with reasonably potent N-channel blocking activity that could be readily derivatized into a cationic molecule. [Figure 1](#fig1){ref-type="fig"} (inset) shows the neutral molecule that we designed for this purpose. Its structure is based on a scaffold of a family of molecules with blocking activity against N-type calcium channels described by [@bib84], although it is not identical to any of the compounds they described. This molecule, which we call NNCB-2 ('NNCB' for 'neutral N-type calcium channel blocker') has a secondary amine group that can be readily converted to a quaternary form to form a cationic molecule, which we call CNCB-2 ('CNCB' for 'cationic N-type calcium channel blocker'). We first examined the efficacy with which the neutral compound inhibits cloned N-type calcium channels ([Figure 1](#fig1){ref-type="fig"}). We found effective and dose-dependent inhibition, with 10 µM NNCB-2 inhibiting calcium channel current by about 60% and 100 µM NNCB-2 producing complete inhibition in about 30 s, when applied at a holding potential of −70 mV, near typical neuronal resting potentials.

![State dependent inhibition of Cav2.2 channels by the neutral compound NNCB-2.\
(**A**) Time course of inhibition of Cav2.2 current by external NNCB-2 applied at concentrations from 3 to 100 µM. Current carried by 5 mM Ba^2+^ was evoked by 50-millisecond steps from −70 to +10 mV delivered every 3 s. Data points show mean SEM (n = 4). Inset: Structure of NNCB-2 (3-Cyclopentylmethylsulfanyl-2-(3,3-dimethyl-butylamino)-N-(4-methoxy-benzyl)-propionamide). (**B**) Inhibition by 10 µM NNCB-2 of Cav2.2 current with current evoked from a holding potential of −70 mV (top) or −100 mV (bottom). (**C**) Test for reversibility of NNCB-2 following exposure for 1 min, using 50 ms test pulses to +10 mV from a holding potential of either −70 mV (n = 3) or −100 mV (n = 7). [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig1){#fig1}

Inhibition by NNCB-2 was voltage-dependent. Compared to inhibition when applied at −70 mV, application at a holding potential of −100 mV produced weaker inhibition that developed more slowly ([Figure 1C](#fig1){ref-type="fig"}).

Inhibition of Cav2.2 channels with external application of cationic CNCB-2 {#s2-2}
--------------------------------------------------------------------------

Studying the cationic molecule CNCB-2, we first tested external application ([Figure 2](#fig2){ref-type="fig"}). CNCB-2 inhibited Cav2.2 channels effectively with external application. Inhibition by CNCB-2 was slower than with the same concentration of the neutral compound, with 100 µM CNCB-2 requiring about 3 min to produce complete inhibition. Similar to inhibition by NNCB-2, inhibition by CNCB-2 was enhanced when channels were activated from a resting potential of −70 mV compared to a resting potential of −100 mV, consistent with state-dependent binding.

![State dependent inhibition of Cav2.2 channels by the charged compound CNCB-2.\
(**A**) Time course of inhibition of Cav2.2 current by external CNCB-2 applied at concentrations from 10 to 300 µM. Current carried by 5 mM Ba^2+^ current was evoked by 50-millisecond steps from −70 to +10 mV delivered every 3 s. Data points show mean ± SEM (n = 4). Inset: Structure of CNCB-2 (\[2-Cyclopentylmethylsulfanyl-1-(4-methoxy-benzylcarbamoyl)-ethyl\]−(3,3-dimethyl-butyl)-dimethyl-ammonium, chloride salt). (**B**) Inhibition by 30 µM CNCB-2 of Cav2.2 current with current evoked from a holding potential of −70 mV (top) or −100 mV (bottom). (**C**) Minimal reversal of CNCB-2 inhibition by washing following exposure for 1 min, using 50 ms test pulses to +10 mV from a holding potential of either −70 mV (n = 9) or −100 mV (n = 7). Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig2){#fig2}

Inhibition by external CNCB-2 does not require channel opening {#s2-3}
--------------------------------------------------------------

One possible interpretation of the slower inhibition by CNCB-2 compared to NNCB-2 would be that the charged compound can only interact with channels when channels are activated, for example if the cationic molecule enters the channel through the open pore. We examined this possibility by testing whether channel opening is necessary for inhibition to develop, by applying the compound in the absence of depolarizing pulses to open the channel ([Figure 3](#fig3){ref-type="fig"}). We found that both NNCB-2 and CNCB-2 were able to inhibit effectively even in the absence of any channel opening. Application of 100 µM CNCB-2 for 3 min in the absence of stimulation resulted in a decrease of current to 33 ± 5% of control (n = 4, measured during the first depolarizing pulse after the 3 min application). Thus, inhibition by CNCB-2 can occur in the absence of channel opening. However, the degree of inhibition produced by a 3 min application of 100 µM CNCB-2 in the absence of depolarizing pulses was less than the inhibition produced when depolarizing pulses were given during the application (50-millisecond steps from −70 to +10 mV delivered every 3 s, [Figure 2](#fig2){ref-type="fig"}), where a 3 min application reduced current to 5 ± 2% of control (n = 4). This is consistent with drug binding being accelerated when channels are open or inactivated, but clearly binding can also occur effectively even in the absence of channel opening. We saw similar effects with application of the neutral NNCB-2: a 3 min application of 30 µM NNCB-2 in the absence of stimulation reduced current to 33 ± 11% of control (n = 4), while application in the presence of stimulation reduced current to 5 ± 1% of control of control (n = 3).

![Test of whether Cav2.2 inhibition by NNCB-2 and CNCB-2 requires channel opening and comparison of internal and external application of CNCB-2 .\
(**A**) Calcium channel inhibition by NNCB-2 or CNCB-2 does not require channel opening. Ba^2+^ current was elicited in a whole-cell recording by 50-millisecond steps from −70 to + 10 mV delivered every 10 s. Five pulses were applied in control solution, then NNCB-2 (n = 4) or CNCB-2 (n = 4 to 5) was applied for 3 min with no activation of channels and then depolarizing pulses were resumed for 50 s (in the continuing presence of drug). Then, the cell was perfused with drug-free solution for 3 min without stimulation and then depolarizing pulses were resumed for 50 s to assay recovery. (**B**) Slow inhibition of N-type Ca^2+^ channels by intracellularly applied CNCB-2. 300 µM CNCB-2 applied in the pipette solution (green triangles) produced inhibition that developed relatively slowly over several minutes (green triangles, mean ± SEM, n = 3). The time course of inhibition was similar to that of 100 µM CNCB-2 applied externally (black circles, mean ± SEM, n = 4) and slower than 300 µM CNCB-2 applied externally (red circles, mean ± SEM, n = 4); data points for external application from [Figure 2](#fig2){ref-type="fig"}. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig3){#fig3}

Slow recovery from CNCB-2 inhibition {#s2-4}
------------------------------------

A major difference between the inhibition produced by the cationic and neutral compounds was that recovery from CNCB-2 inhibition was much slower than from NNCB-2 when the agent was removed ([Figure 3A](#fig3){ref-type="fig"}). With 3 min of wash-out after exposure to 100 µM NNCB-2, current recovered from −1 ± 11% to 81 ± 10% (n = 4) of the initial control value before compound was applied. However, with 3 min of wash-out after exposure to 100 µM CNCB-2, current recovered much less, from 11 ± 6% to 28 ± 4% (n = 4). Thus, although inhibition by CNCB-2 develops somewhat more slowly than that by NNCB-2, CNCB-2 binding to the channel appears to be tighter and reverses more slowly.

Internal application of CNCB-2 {#s2-5}
------------------------------

We next tested internal application of CNCB-2. Applying CNCB-2 internally by inclusion in the pipette solution produced inhibition of Cav2.2 calcium channel current that developed over the first several minutes of dialysis ([Figure 3B](#fig3){ref-type="fig"}). However, inhibition by internal CNCB-2 developed more slowly than with external application. With 300 µM CNCB-2 applied internally, current was reduced to 20% of the initial control value after 114 s, while the same reduction took only 27 s with external application of 300 µM CNCB-2. In fact, the time course of inhibition by internally-applied 300 µM CNCB-2 was similar to the time course of inhibition by 100 µM CNCB-2 applied externally.

Inhibition of native calcium channels {#s2-6}
-------------------------------------

To examine whether CNCB-2 applied externally can inhibit native N-type calcium channels in neurons as well as cloned N-type channels expressed in HEK cells, we tested its effects on calcium channels in mouse superior cervical ganglion (SCG) sympathetic neurons, a neuronal type in which \~ 80--90% of the overall voltage-dependent calcium current is carried by N-type calcium channels ([@bib79]). Externally applied CNCB-2 was effective in inhibiting calcium channel current in SCG neurons, with an IC~50~ near 3 µM ([Figure 4](#fig4){ref-type="fig"}). As for heterologously expressed channels, inhibition was long-lasting, with very little reversal of inhibition over several minutes of washing with drug-free solution.

![Dose-dependent inhibition of native N-type Ca^2+^ channels in mouse sympathetic neurons by CNCB-2 applied extracellularly.\
(**A**) Time course of inhibition by 10 µM CNCB-2. Current carried by 5 mM Ba2^+^ was evoked by 50 ms steps from −70 to +10 mV delivered every 3 s. The external solution contained 5 μM nimodipine to block L-type calcium channels and 1 μM TTX to block sodium channels. Inset: Current before and after application of CNCB-2. Tail currents in control trace are truncated. (**B**) Current remaining in CNCB-2 applied at 3, 10, or 30 µM (mean ± SEM, n = 5 for 3 and 10 μM CNCB-2, n = 6 for 30 µM CNCB-2). Experiments performed at 37°C. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig4){#fig4}

Inhibition of Nav1.7 channels {#s2-7}
-----------------------------

We expected that CNCB-2 would have selectivity for N-type calcium channels, because the parent compound was based on a family described as being selective N-type calcium channel inhibitors ([@bib84]). Surprisingly, however, we found that CNCB-2 also inhibits sodium channels with external application, acting even more potently on sodium channels than on N-type calcium channels. [Figure 5A](#fig5){ref-type="fig"} shows the effect of 3 µM CNCB-2 applied to Nav1.7 sodium channels expressed in a stable cell line. With a holding potential of −70 mV and 10-msec depolarizing steps to 0 mV delivered every 5 s, 3 µM CNCB-2 inhibited sodium current to 31 ± 5% of control with application for 10 min (n = 5). Inhibition of Nav1.7 channels by CNCB-2 was voltage-dependent, with more potent inhibition from more depolarized holding potentials, in a manner suggesting higher-affinity binding to inactivated states of the sodium channel. Using a protocol in which various holding voltages were established for 2 s in a staircase-like manner, 3 µM CNCB-2 produced equal inhibition at holding voltages of −120 mV and −100 mV (to 67 ± 5% of control at −120 mV and to 67 ± 4% of control at −100 mV), where channels are in the resting state, but much more effective inhibition at more depolarized voltages where more channels are in inactivated states, inhibiting to 12 ± 4% of control from a holding potential of −60 mV where \~ 55% of channels are in the inactivated state under control conditions (n = 5 for all measurements). The relationship of channel availability to voltage with and without CNCB-2 can be used to estimate the binding affinity of CNCB-2 to resting and inactivated channels, using the relation ΔV~h~ = k\*ln\[(1+C/K~R~)/(1+C/K~I~)\], where ΔV~h~ is the shift in the midpoint of channel availability produced by the compound, k is the slope factor of the Boltzmann availability curve, C is the concentration of CNCB-2, and K~R~ and K~I~ are the equilibrium constants for CNCB-2 binding to the resting and inactivated states, respectively ([@bib6]). Making this calculation (and using the inhibition at −120 mV where channels are all in the resting state to estimate K~R~) results in estimates of K~R~ = 5.6 µM and K~I~ = 0.71 µM. This can be compared to the estimates of K~R~ = 440 µM and K~I~ = 10 µM for lidocaine binding to sodium channels ([@bib6]), implying much tighter binding of CNCB-2 than lidocaine to both resting and inactivated states of the channel.

![CNCB-2 applied extracellularly inhibits Nav1.7 sodium channels.\
(**A**) Time course of inhibition by 3 µM CNCB-2. Current was evoked by 10 ms steps from −70 to 0 mV delivered every 5 s. Mean ± SEM, n = 5. (**B**) Inhibition by 3 µM CNCB-2 at different holding potentials. Each holding potential was established for 2 s before a test pulse to 0 mV. (**C**) Collected results showing inhibition by 3 µM CNCB-2 as a function of holding potential, with current normalized to largest current in control (from a holding potential of −120 mV). Filled symbols show mean ± SEM, n = 5. Solid lines are drawn according to the Boltzmann equation 1/(1 + exp((V - V~h~)/k)), where V is holding voltage, V~h~ is voltage of half-maximal availability, and k is the slope factor. Control: Vh = −63 mV, k = 6.5 mV; 3 µM CNCB-2: Vh = −71 mV, k = 7.2 mV. Dashed red line: fit for CNCB-2 data scaled to 1. Experiments performed at 37°C. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig5){#fig5}

Inhibition of Nav1.7 channels by CNCB-2 was strongly-use-dependent. Both the rate of inhibition and the degree of inhibition were greater with more rapid stimulation ([Figure 6A](#fig6){ref-type="fig"}). The use-dependent inhibition by CNCB-2 was more potent than that by lidocaine or even by bupivacaine, the most potent of local anesthetics commonly used clinically ([@bib7]). In the absence of drug, 2 min of stimulation at 10 Hz reduced current to 77 ± 3% (n = 12), reflecting accumulation into a slow inactivated state from which current recovered quickly on a return to 0.1 Hz stimulation. With 3 µM CNCB-2, current during the 10 Hz stimulation was reduced to 14 ± 8% of control (n = 5), with only slow and partial recovery of current when stimulation was returned to 0.1 Hz. The use-dependent reduction by 3 µM CNCB-2 was more pronounced than by 30 µM lidocaine (reduction to 57 ± 7% of control, n = 6) and similar to 10 µM bupivacaine (reduction to 22 ± 4%, n = 5), with much slower reversal than either lidocaine or bupivacaine when returning to 0.1 Hz stimulation ([Figure 6](#fig6){ref-type="fig"}).

![Use-dependent inhibition of Nav1.7 sodium channels by externally-applied CNCB-2 compared to lidocaine and bupivacaine.\
(**A**) Inhibition of Nav1.7 current by 3 µM CNCB-2 applied with stimulation at 0.1 Hz (20-msec depolarizations from −100 mV to 0 mV) for two minutes followed by two minutes of stimulation at 10 Hz, a return to 0.1 Hz stimulation and wash-out of compound. Black symbols: same pulse protocol in the absence of drug, recorded before application of drug. (**B**) Same protocol with 30 µM lidocaine. (**C**) Same protocol with 10 µM bupivacaine. (**D**) Collected results showing current at the end of 2 min of 10 Hz stimulation relative to that before application of drug. Mean ± SEM, n = 12 for no drug, n = 5 for 3 µM CNCB-2, n = 6 for 30 µM lidocaine, n = 5 for 10 µM bupivacaine. Experiments performed at 37°C. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig6){#fig6}

As for Cav2.2 channels, CNCB-2 applied internally had weaker effects on Nav1.7 channels than when applied externally. In three cells, CNCB-2 applied internally at 3 µM produced very little inhibition even with 2--3 series of 2 min stimulation at 10 Hz. However, when 3 µM CNCB-2 was then applied externally, it immediately produced inhibition during the stimulation at 10 Hz, exactly as when external 3 µM CNCB-2 was applied in the absence of internal CNCB-2. Thus, it appears that CNCB-2 accesses its binding sites on both Nav1.7 and Cav2.2 channels most easily from the external surface of the membrane.

Inhibition of sensory neuron excitability {#s2-8}
-----------------------------------------

The inhibition of Nav1.7 channels suggests that CNCB-2 may reduce electrical excitability of primary sensory neurons, where Nav1.7 channels contribute to overall TTX-sensitive sodium current ([@bib89]). We tested this possibility using dissociated dorsal root ganglion neurons, focusing on a population of small diameter DRG neurons that express both TTX-sensitive and TTX-resistant sodium channels, most of which correspond to C-fiber nociceptors. We found that CNCB-2 potently inhibits action potential firing in these neurons. [Figure 7A](#fig7){ref-type="fig"} shows a typical example, in which the neuron fired multiple large-amplitude action potentials during depolarizing current injections in control conditions but only a single action potential of reduced size after application of 3 µM CNCB-2, even with large current injections. In addition to dramatically depressing action potential firing, application of CNCB-2 produced a depolarization of the resting potential of the neurons, from −76 ± 2 mV in control to −62 ± 3 mV (n = 5) after application of 3 µM CNCB-2. This depolarization of the resting potential was never enough to stimulate firing of the neurons (which had an average threshold voltage of −32 ± 1 mV, n = 8). Because the depression of action potential firing could in principle be partly due to inactivation of sodium channels as a result of the more depolarized resting potential, we also did a series of experiments in which the resting potential of the neurons was adjusted by steady holding current to the same voltage as in control. The action potential firing was also strongly inhibited in these neurons. On average, the number of action potentials evoked by a 1 s 80 pA current injection was reduced from 18 ± 8 in control to 0.6 ± 0.2 after application of 3 µM CNCB-2 (n = 5), similar to the depression of firing in an earlier series in which resting potential was not adjusted (13 ± 2 spikes in control to 2 ± 1 after application of 3 µM CNCB-2, n = 5).

![Inhibition of action potential generation in mouse DRG neurons by CNCB-2.\
(**A**) Action potential firing evoked by injections of 40 pA, 150 pA, and 200 pA in a small-diameter mouse DRG neuron before and after 5 min exposure to 3 µM CNCB-2. Resting potential in CNCB-2 was adjusted to match the resting potential in control (near −67 mV) by injection of −20 pA. (**B**) Collected results showing the number of action potentials evoked by 1 s current injections of increasing sizes before and after 5 min exposure to 3 µM CNCB-2. Resting potentials in CNCB-2 were adjusted to match the resting potential in control by injection of steady holding current. Mean ± SEM, n = 4. Experiments at 37°C. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig7){#fig7}

In addition to the reduction in the number of action potentials evoked by current injection, CNCB-2 dramatically depressed the peak of the action potential (from +30 ± 3 mV in control to −2 ± 2 mV in 3 µM CNCB-2, n = 4, holding potential adjusted in CNCB-2).

Inhibition of TTX-resistant sodium channels {#s2-9}
-------------------------------------------

The action potential in small diameter nociceptive DRG neurons is mediated by a combination of TTX-sensitive sodium current, which helps initiate the action potential, and TTX-resistant sodium current, carried mainly by Nav1.8 channels, which generally provides the majority of total sodium current during the action potential ([@bib80]; [@bib12]). The dramatic reduction in the magnitude of the action potential by CNCB-2 suggested that CNCB-2 might inhibit TTX-resistant as well as TTX-sensitive sodium channels. We tested this in voltage clamp experiments and found that CNCB-2 effectively inhibited both TTX-sensitive and TTX-resistant components of sodium current in DRG neurons. In a first series of experiments, we found that 30 µM CNCB-2 inhibited overall sodium current in small DRG neurons nearly completely (reduction to 4 ± 1% of control, n = 10, CNCB-2 applied for 2.5--5 min). We then examined TTX-resistant sodium current in isolation and tested lower concentrations of CNCB-2 ([Figure 8](#fig8){ref-type="fig"}). At 3 µM, CNCB-2 inhibited TTX-resistant sodium current to 23 ± 6% of control (n = 6) and 10 µM CNCB-2 inhibited TTX-resistant sodium current to 10 ± 3% of control (n = 4).

![Inhibition of TTX-resistant sodium current in mouse DRG neurons by CNCB-2.\
(**A**) Time-course of inhibition of TTX-resistant sodium current in a small mouse DRG neuron by 3 µM CNCB-2. TTX-resistant sodium current was isolated by solutions containing 300 nM TTX. Current was evoked by a 10-msec step depolarization from −80 mV to −10 mV delivered once every 5 s. Inset: currents before and after CNCB-2. (**B**) Collected results showing current after application of 3 µM CNCB-2 (n = 6) or 10 µM CNCB-2 (n = 4) for long enough to reach steady-state (10--15 min for 3 µM CNCB-2 and 5--10 min for 10 µM CNCB-2). Experiments at 37°C. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig8){#fig8}

Effects in a paw incision model of post-operative pain {#s2-10}
------------------------------------------------------

The efficacy with which CNCB-2 inhibited sodium channels and action potential firing in DRG neurons suggests that it could be an effective analgesic. We tested CNCB-2 in several in vivo rodent models of pain. We first tested it in the rodent paw incision model of post-operative pain ([@bib14]; [@bib91]; [@bib25]) which produces hyperalgesia mimicking many features of human post-operative pain, including mechanical hypersensitivity, and responds in a similar manner to many pharmacological interventions ([@bib102]; [@bib15]). Based on the more potent action of CNCB-2 to produce use-dependent sodium channel inhibition compared to bupivacaine, we tested injections of CNCB-2 at concentrations of 15 mM or 30 mM in a 10 μL volume of injectant and compared their effect with that of 30 mM bupivacaine (\~0.5%, the usual concentration of bupivacaine used clinically). Twenty-four hours after the incision, a single injection of 10 μL of either 15 mM or 30 mM CNCB-2 directly adjacent to the incision resulted in a reduction of mechanical sensitivity that lasted for at least 8 hr ([Figure 9A](#fig9){ref-type="fig"}). In contrast, 30 mM bupivacaine produced no remaining analgesic effect 1 hr after injection, in marked contrast to the long-lasting effects of CNCB-2. The short duration of action of bupivacaine in this model is consistent with a previous study in which bupivacaine injected alone without norepinephrine (generally co-applied with bupivacaine in clinical settings to produce vasoconstriction and thereby slow washout of bupivacaine by blood flow) had effects lasting only 25 min ([@bib39]).

![Effect of CNCB-2 in mouse pain models.\
(**A**) Inhibition of paw withdrawal in paw incision model of post-operative pain. Threshold for response to von Frey filaments tested 1, 4 and 8 hr after injection of CNCB-2 into an injured paw 24 hr after the incisional injury (5 mm incision). Mean ± SEM for 50% withdrawal threshold (n = 8 for each group). (**B**) Inhibition by CNCB-2 of paw withdrawal in the zymosan model of inflammatory pain. Either 10 μL of CNCB-2 (30 mM) or vehicle (5% DMSO in normal saline) was injected in hind paw. One hour later the same paw was injected subcutaneously with 20 μL of zymosan (5 mg/ml in saline) and tested 4 hr after the zymosan injection by the von Frey test (Mean ± SEM for 50% withdrawal threshold, n = 5 for each group). (**C**) Direct analgesic effect of CNCB-2: inhibition of paw withdrawal by 10 μL of CNCB-2 (30 mM) injected into uninjured paws (n = 8 for each group). Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig9){#fig9}

Zymosan model of inflammatory pain {#s2-11}
----------------------------------

We also tested CNCB-2 in a widely-used mouse model of inflammatory pain, in which intraplantar injection of zymosan into the footpad induces inflammation and mechanical and thermal hypersensitivity, mimicking human inflammatory pain ([@bib65]; [@bib24]). CNCB-2 was exceptionally effective in this model ([Figure 9B](#fig9){ref-type="fig"}), increasing the 50% withdrawal threshold from 0.20 ± 0.08 grams to 3.6 ± 0.2 grams (n = 5) of pressure.

Analgesia of uninjured tissue {#s2-12}
-----------------------------

The cationic lidocaine derivative QX-314 can inhibit signaling by nociceptors if applied together with activators of TRPV1 or TRPA1 channels ([@bib10]; [@bib56]; [@bib67]), which have pores large enough to allow entry of QX-314 into neurons. Because CNCB-2 inhibits sodium channels directly from the outside of the cell, there should be no requirement for co-administration with TRPV1 or TRPA1 activators or for endogenous activation of these channels such as might occur during tissue damage or inflammation. We therefore tested the ability of CNCB-2 to inhibit pain signaling when injected into uninjured paws. CNCB-2 produced effective analgesia when injected in paws of naïve mice, with analgesia lasting for at least 4 hr ([Figure 9C](#fig9){ref-type="fig"}).

Inhibition of neuropeptide release from cultured DRG neurons {#s2-13}
------------------------------------------------------------

Calcium entry through N-type calcium channels triggers release of neuropeptides from primary sensory neurons by activating vesicular release ([@bib45]; [@bib30]; [@bib22]; [@bib4]; [@bib94]). We therefore tested the ability of the charged and uncharged inhibitors to reduce release of CGRP, a peptide implicated in pain, migraine and inflammation, from dorsal root ganglion neurons. Studying release of CGRP from cultured DRG neurons induced by depolarization (exposure to 50 mM KCl), we found that both NNCB-2 and CNCB-2 were able to reduce CGRP release, with greater efficacy of inhibition by CNCB-2. CGRP release in this model likely involves calcium entry through L-type ([@bib30]) as well as N-type ([@bib22]) calcium channels and possibly calcium entry through P-type and R-type calcium channels that are also present in DRG neurons ([@bib79]). Further analysis of the calcium entry pathways mediating CGRP release would be required to interpret the greater efficacy of CNCB-2 in this system.

Action on allergic lung inflammation {#s2-14}
------------------------------------

Release of pro-inflammatory peptides from primary sensory neurons is part of a neuro-immune positive feedback cycle involved in a number of inflammatory processes with a neurogenic component ([@bib23]; [@bib32]), including a mouse model of asthma ([@bib95]). In this model, an allergic reaction to ovalbumin is induced, after which a challenge by nebulized ovalbumin produces airway inflammation, which can be assayed by quantification of immune cells present in bronchoalveolar lavage fluid. Lung inflammation in this model has a strong neurogenic component and can be greatly reduced either by ablation of primary sensory neurons or by blocking their excitability by QX-314 entry through large-pore channels activated during inflammation ([@bib95]). We tested whether local administration of CNCB-2 could resolve inflammation after it was induced in this model, with the idea that on-going neuropeptide release from the peripheral terminals of sensory neurons may underlie the inflammation. Based on the ability of 30 µM CNCB-2 to reduce peptide release from sensory neurons in vitro, we tested this concentration of CNCB-2 in vivo, applied after lung inflammation had been produced by ovalbumin sensitization and 4 days of daily exposure to nebulized ovalbumin. At this point (day 18 of protocol shown in time-line, [Figure 10B](#fig10){ref-type="fig"}), lung inflammation is near its peak. With the expectation that reducing neuropeptide release could produce a long-lasting reduction in the neurogenic component of inflammation, the effect of the CNCB-2 exposure was measured 3 days after the CNCB-2 exposure by assaying immune cells in bronchoalveolar lavage fluid. Exposure to 30 µM CNCB-2 dramatically reduced lung inflammation compared to exposure to vehicle, with a reduction of CD3^+^ cells (lymphocytes) to \~20% of the levels with no CNCB-2 exposure and reductions to 25--35% for the other inflammation-associated immune cell types tested ([Figure 10B](#fig10){ref-type="fig"}). We compared the effect of 30 µM CNCB-2 with that of 100 µM NNCB-2, selecting a higher concentration based on the lesser efficacy of the neutral compound in the in vitro experiments with CGRP release in [Figure 10A](#fig10){ref-type="fig"}. In keeping with a greater efficacy of CNCB-2 in this model, the effects of 100 µM NNCB-2 were quantitatively very similar to those of 30 µM CNCB-2. We conclude that topical administration of CNCB-2 is an effective way to inhibit the neurogenic component of allergic inflammation in a long-lasting manner.

![Inhibition of CGRP release and neurogenic lung inflammation by NNCB-2 and CNCB-2.\
(**A**) Effect of 30 µM NNCB-2 or 30 µM CNCB-2 on release of CGRP induced by application of 50 mM KCl to DRG cultures (p=0.15 for 30 µM NNCB-2 (n = 4) compared to 50 mM KCl with no drug (n = 4), p=0.028 for 30 µM CNCB-2 (n = 8) compared to 50 mM KCl with no drug (n = 4); one-tailed t-test for non-homoscedastic data). (**B**) Effect of 100 µM NNCB-2 or 30 µM CNCB-2 on inflammation-associated immune cells in broncheoalveolar lavage fluid in lungs from mice with ovalbumin-induced lung inflammation. p=0.019 for CD45^+^ cells from ovalbumin-exposed mice application of 100 µM NNCB-2 (n = 8) compared to vehicle (n = 8); p=0.014 for CD45^+^ cells from ovalbumin-exposed mice with application of 30 µM CNCB-2 (n = 7) compared to vehicle (n = 8). p=0.031 for CD3^+^ cells from ovalbumin-exposed mice with application of 100 µM NNCB-2 (n = 8) compared to vehicle (n = 8); p=0.028 for CD3^+^ cells from ovalbumin-exposed mice with application of 30 µM CNCB-2 (n = 7) compared to vehicle (n = 8). p=0.10 for macrophages from ovalbumin-exposed mice with application of 100 µM NNCB-2 (n = 8) compared to vehicle (n = 8); p=0.11 for macrophages from ovalbumin-exposed mice with application of 30 µM CNCB-2 (n = 7) compared to vehicle (n = 8). p=0.008 for eosinophils from ovalbumin-exposed mice with application of 100 µM NNCB-2 (n = 8) compared to vehicle (n = 8); p=0.005 for eosinophils from ovalbumin-exposed mice with application of 30 µM CNCB-2 (n = 7) compared to vehicle (n = 8); one-tailed t-test for non-homoscedastic data. Source data can be found in [Source data 1](#sdata1){ref-type="supplementary-material"}.](elife-48118-fig10){#fig10}

Discussion {#s3}
==========

Originally, our intention was to design a cationic molecule that would inhibit N-type calcium channels by entering neurons through TRPV1 or other large-pore channels, a strategy we used previously for QX-314 inhibition of sodium channels that can produce long-lasting analgesia ([@bib10]; [@bib11]). We had two major surprises in the course of the work: first, that the charged version of the N-type calcium channel inhibitor was more effective in inhibiting N-type calcium channels with external than with internal application, in striking contrast to the charged lidocaine derivative QX-314, which acts only with intracellular application and has no effect when applied extracellularly ([@bib33]; [@bib10]) and second, that the molecule is also a highly effective inhibitor of sodium channels when applied externally.

For both calcium and sodium channels, inhibition by CNCB-2 was enhanced if applied at more depolarized membrane potentials. This effect most likely reflects a dependence of binding on the gating state of the channel rather than some intrinsically voltage-dependent binding reaction, because the effect saturated when voltages were sufficiently negative to ensure that almost channels are in the resting non-inactivated state. Preferential binding to inactivated states of the channel is characteristic of many non-permanently charged small molecule inhibitors of both sodium and calcium channels ([@bib54]; [@bib55]; [@bib93]): [@bib50]). Interestingly, however, QX-314 inhibition of sodium channels is qualitatively different from that of uncharged molecules in that QX-314 entry and exit appear to occur only when the channel is actually open ([@bib18]). In contrast, CNCB-2, like lidocaine, can clearly bind to inactivated channels in the absence of any significant channel opening.

Further work will be required to understand the molecular interactions that make it possible for charged CNCB-2 to interact with channels when applied externally. It seems unlikely that the inhibition by externally applied CNCB-2 represents movement through the membrane into the intracellular solution followed by entry into the internal mouth of the pore, because externally applied CNCB-2 acted much more rapidly than the same concentration applied directly inside the cell (for inhibition of both Cav2.2 and Nav1.7 channels). More plausible is access to a binding site on or in the channel that does not require complete translocation of the CNCB-2 molecule across the membrane. One possibility is that there could be partial entry into the bilayer of the more hydrophobic regions of the molecule so that the molecule localizes to the interface between lipid bilayer and the channel, perhaps even the voltage-sensing regions of the channel, analogous to the interaction seen with various toxins that interact with the gating regions of voltage-dependent channels ([@bib40]; [@bib43]). Another possibility is that the CNCB-2 molecule can somehow enter the pore region of the channel without first translocating to the cytosol. Recent molecular modeling enabled by cryo-EM structures of eukaryotic sodium channels suggests that the charged (protonated) form of lidocaine binds in the pore domain, with the cationic region of the molecule near the selectivity filter, partially displacing sodium ions in the selectivity filter ([@bib16]; [@bib69]). Modeling shows that the binding site for lidocaine in sodium channels can accommodate two lidocaine molecules ([@bib69]), suggesting that the same intra-pore binding site could also accommodate the larger CNCB-2 molecule (MW 435 Daltons vs 234 Daltons for lidocaine). An intriguing possibility raised by [@bib69] is that a charged molecule like protonated lidocaine could enter the pore through 'fenestrations' in the pore forming regions of Domain III and Domain IV, as the uncharged form of lidocaine likely does ([@bib34]), and they suggest that external QX-314 might enter the pore of Nav1.5 cardiac sodium channels by this pathway. However, molecular dynamic modeling on the scale of a few μsec cannot directly show the likelihood of such movements, which would be far slower, so this remains speculative. It is also not obvious why in neuronal sodium channels CNCB-2 could enter by this pathway if the smaller QX-314 molecule does not. Further experimental studies with a variety of cationic molecules will be needed to understand the structural characteristics enabling access from the external surface, complemented with the kind of molecular modeling done with lidocaine and QX-314 to understand likely binding sites within the channel. So far such modeling has been done for lidocaine binding to the inactivated state of the channel; similar modeling for interaction with resting state channels would be difficult with lidocaine, since the affinity is so low, but should be more feasible for CNCB-2, with its \~ 100 fold higher affinity than lidocaine for interacting with resting channels.

Molecular modeling may also be useful to understand why inhibition with CNCB-2 applied internally is slower than with external application in both Cav2.2 channels and Nav1.7 channels, a surprising result given the opposite behavior of QX-314. We cannot rule out the possibility that the inhibition by 300 µM internal CNCB-2 seen in Cav2.2 channels reflects slow movement of CNCB-2 molecules from the cytoplasmic side of the membrane to the external leaflet, especially because in these experiments the external medium was not flowing. A more general caveat for interpreting experiments with internal application of compounds in whole-cell recording is the inherent difficulty to accurately control the concentration of the compounds seen at the membrane, which reflects a combination of diffusion from the pipette and entry into or through the bilayer ([@bib46]). Application with inside-out patches could better define the kinetics and concentration- dependence of internally applied CNCB-2 but such experiments would be technically challenging because of the requirement for long-lived patches given the slow action of CNCB-2.

Sodium channel inhibition by external application has been reported for several other cationic small molecules, notably cationic derivatives of amitriptyline and duloxetine ([@bib36]; [@bib100]), tricyclic molecules introduced clinically as antidepressants that have become first-line treatments for neuropathic pain ([@bib28]) where they may act in part by inhibition of sodium channels ([@bib26]). Inhibition by N-methyl-duloxetine was modulated by membrane potential in a manner consistent with preferential binding to inactivated channels, as we saw for CNCB-2 ([@bib100]). However, the interaction of CNCB-2 with sodium channels (estimated K~R~ of 5.6 µM and K~I~ of 0.71 µM) is far more potent than for N-methyl-duloxetine (estimated K~R~ of 138 µM and K~I~ of 2.8 µM), especially for interacting with the resting state of the channel. In fact, the high potency of resting channel inhibition by CNCB-2 stands out when compared with a systematic study of a large range of non-cationic sodium channel inhibitors ([@bib54]), where the lowest value of K~R~ found was 21 µM (for the tricyclic antidepressant paroxetine) and most are \>100 µM.

This is the first test of a charged inhibitor of N-type calcium channels. A number of previous studies have examined inhibition of cardiac L-type calcium (Cav1.2) channels by charged derivatives of various small molecule inhibitors. Interestingly, different chemical classes of L-type calcium channel inhibitors behave very differently. A charged derivative of the benzothiazepine drug diltiazem behaves much like the QX-314 mediated inhibition of sodium channels, with little effect with external application but able to inhibit with intracellular application in a strongly use-dependent manner, as if the compound can enter channels from the inside and only when channels are open ([@bib87]). Several charged derivatives of the phenylalkylamine verapamil also produce strong use-dependent inhibition with internal application with no effect on external application (although one derivative did produce significant non-use-dependent inhibition with external application; [@bib8]). In contrast, however, charged versions of the dihydropyridine class of calcium channel inhibitors have the opposite behavior, producing inhibition only with external application and having no effect when applied inside the cell ([@bib47]). It would be informative to explore possible parallels at the structural level in the ways in which CNCB-2 and charged dihydropyridine molecules are able to interact with various calcium and sodium channels from the outside.

Recent efforts to find new analgesics targeting sodium channels have focused on compounds that have high selectivity for Nav1.7 or Nav1.8 channels (e.g. [@bib111]; [@bib48]; [@bib104]; reviewed by [@bib107]) which are expressed in nociceptors but have little or no expression in heart or brain. Selectivity among sodium channel subtypes, or for sodium channels over other channel types, may be important for neutral compounds that are present systemically. However, the ability to non-selectively inhibit a wide range of sodium channels may actually be advantageous for a charged compound administered locally, because nociceptive neurons express a range of sodium channels ([@bib112]) and inhibiting only one of them may not effectively block excitability. This may be a reason for the disappointing clinical results so far ([@bib107]), with the new generation of highly selective Nav1.7 inhibitors that bind with high affinity to external sites on Nav1.7 channels by means of a negatively charged 'warhead' region that interacts with externally-oriented parts of voltage-sensing regions ([@bib3]). Based on its similarly potent inhibition of Cav2.2 channels, Nav1.7 channels, and native TTX-sensitive and TTX-resistant channels, CNCB-2 is likely to inhibit a wide range of voltage-dependent channels. However, systemic exposure is likely to be very low, since the charged molecule is unlikely to penetrate well through tissue into the blood stream, which should minimize unwanted effects in tissues away from the site of application, including the heart and brain, unlike local application of anesthetics like lidocaine and bupivacaine.

It is remarkable that externally applied CNCB-2 inhibits sodium channels more potently than bupivacaine, one of the most potent local anesthetics. Recent work has introduced preparations of bupivacaine delivered in liposomes designed for slow release and longer-lasting effects when applied to wounds during surgery ([@bib2]). The intrinsically higher potency and expected slower diffusion away from the site of application -- as reflected in the long durations of action we saw in the mouse paw incision model - may make cationic CNCB-2 ideal for such applications even without packaging in liposomes, and its much greater solubility in aqueous solutions may facilitate its use in various other slow-release technologies for even longer-lasting local pain inhibition.

The dual inhibition of both sodium channels and calcium channels may make CNCB-2 or derivatives especially well-suited for treating inflammatory pain. Many kinds of inflammation involve a 'vicious cycle' of interactions between immune cells and nociceptor sensory neuron endings, in which inflammatory mediators from immune cells stimulate the neurons to release neuropeptides like CGRP, substance P, and VIP, which enhance local immune influx by producing vasodilation and increasing capillary permeability and can directly activate immune cells to release more cytokines ([@bib23]; [@bib32]; [@bib59]; [@bib62]; [@bib70]; [@bib81]; [@bib95]). A key element in neurogenic inflammation is calcium entry into neurons through voltage-dependent calcium channels, which triggers release of peptide-containing vesicles. In particular, N-type (Cav2.2) calcium channels mediate the neuronal release of neuropeptides and are found to be highly expressed in peptidergic primary sensory neurons involved in neurogenic inflammation ([@bib4]; [@bib27]; [@bib45]; [@bib94]). Inhibiting N-type channels with CNCB-2 constitutes a novel approach to reducing inflammation by inhibiting release of neuropeptides. Inhibiting N-type calcium channels should inhibit release of all neuropeptides, which may be more effective than targeting only one peptide, as, for example, in the current use of antibodies that target CGRP or its receptor to treat the vascular component of migraine ([@bib78]; [@bib64]). QX-314 also inhibits peptide release, presumably by reducing the depolarization that activates voltage-gated calcium channels ([@bib95]). CNCB-2 direct inhibition of Cav2.2 as well as sodium channels provides two mechanisms of reducing peptide release, which may increase the efficacy of the compound as an anti-inflammatory; CNCB-2 is more effective at 30 μM ([Figure 10](#fig10){ref-type="fig"}) than 100 μM QX-314 ([@bib95]). Unlike QX-314 which will only enter cells in the presence of activated large pore channels, a feature of active inflammation, CNCB-2 can act even before inflammation is present, potentially preventing its establishment.

We validated this approach to treating inflammation using the clinically relevant mouse model of allergic airway disease ([@bib32]) in which inflammation levels can be easily measured by immunophenotyping the number and activation of immune cells in bronchoalveolar lavage fluid. The ability of combined calcium and sodium channel inhibition to reduce allergic airway inflammation is consistent with extensive evidence of a strong involvement of neuropeptide release in this form of inflammation ([@bib17]; [@bib76]; [@bib95]; [@bib98]) and with the effect of sodium channel blockade with QX-314 in this model ([@bib95]). Other kinds of disease-associated inflammation known to critically involve release of inflammatory neuropeptides include atopic dermatitis ([@bib5]; [@bib38]; [@bib66]), itch ([@bib103]; [@bib71]), psoriasis ([@bib62]; [@bib61]), inflammatory bowel disease and colitis ([@bib20]; [@bib21]; [@bib29]; [@bib51]), arthritis ([@bib49]; [@bib99]; [@bib9]) and ocular inflammation ([@bib63]). We therefore believe this neuronal targeted approach can potentially be used to treat many cutaneous or mucosal inflammatory conditions, where CNCB-2 is well-suited for local application by injection, inhalation, or topical application.

The recent scientific and patent literature has reported a wide range of uncharged compounds effective as N-type calcium channel blockers ([@bib1]; [@bib72]; [@bib74]; [@bib85]; [@bib86]; [@bib88]; [@bib105]; [@bib108]), and many of these have structures that can be modified into cationic versions. Our results suggest that making cationic versions of such molecules that have external blocking activity on calcium and sodium channels may be an unexpected new route to identifying new powerful agents well-suited for both treating pain from injury and surgery and inflammatory conditions with a neurogenic component.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type              Designation                                                                                                                          Source or reference                                              Identifiers                                                    Additional\
                                                                                                                                                                                                                                                                                                 information
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------------
  Strain (*Mus musculus*)   Swiss Webster CFW                                                                                                                    Charles River                                                    Cat\#024                                                       

  Strain (*Mus musculus*)   C57BL6/J                                                                                                                             Jackson Lab                                                      000664                                                         

  Strain (*Mus musculus*)   BALB/c                                                                                                                               Jackson Lab                                                      001026                                                         

  Cell line                 rat Cav2.2 tsA201 cell line                                                                                                          PMID: [15201306](https://www.ncbi.nlm.nih.gov/pubmed/15201306)   Line \#201719                                                  Dr. Diane Lipscombe, Brown University

  Cell line                 human Nav1.7 HEK cell line                                                                                                           PMID: [22442564](https://www.ncbi.nlm.nih.gov/pubmed/22442564)                                                                  Dr. Sooyeon Jo,\
                                                                                                                                                                                                                                                                                                 Harvard Medical School

  Antibody                  FITC anti-mouse CD45                                                                                                                 BD Biosciences                                                   Cat 553079\                                                    
                                                                                                                                                                                                                                  RRID:[AB_394609](https://scicrunch.org/resolver/AB_394609)     

  Antibody                  PR anti-mouse Siglec-F                                                                                                               BD Biosciences                                                   Cat 552126\                                                    
                                                                                                                                                                                                                                  RRID:[AB_394341](https://scicrunch.org/resolver/AB_394341)     

  Antibody                  APC anti-mouse GR-1                                                                                                                  Thermo Fisher                                                    Cat\                                                           
                                                                                                                                                                                                                                  17-5931-81\                                                    
                                                                                                                                                                                                                                  RRID:[AB_469475](https://scicrunch.org/resolver/AB_469475)     

  Antibody                  PE-Cy7 anti-mouse CD3e                                                                                                               Thermo Fisher                                                    Cat 25-0031-81\                                                
                                                                                                                                                                                                                                  RRID:[AB_469571](https://scicrunch.org/resolver/AB_469571)     

  Antibody                  PerCP anti-mouse F4/80                                                                                                               Biolegend                                                        Cat 123125\                                                    
                                                                                                                                                                                                                                  RRID:[AB_893495](https://scicrunch.org/resolver/AB_893495)     

  Commercial assay or kit   MycoAlert PLUS Mycoplasma Detection Kit                                                                                              Lonza                                                            LT07-703                                                       

  Commercial assay or kit   Rat CGRP Enzyme Immunoassay Kit                                                                                                      Bertin Pharma/Cayman Chemical                                    \#589001                                                       

  Chemical compound         NNCB-2 (3-Cyclopentylmethylsulfanyl-2-(3,3-dimethyl-butylamino)-N-(4-methoxy-benzyl)-propionamide)                                   This paper                                                                                                                      Synthesized by Sundia MediTech, structure verified by NMR and mass spectrometry.

  Chemical compound         CNCB-2 (\[2-Cyclopentylmethylsulfanyl-1-(4-methoxy-benzylcarbamoyl)-ethyl\]−(3,3-dimethyl-butyl)-dimethyl-ammonium; chloride salt)   This paper                                                                                                                      Synthesized by Sundia MediTech, structure verified by NMR and mass spectrometry.

  Chemical compound         Papain                                                                                                                               Worthington Biochemical                                          LS003126                                                       

  Chemical compound         Collagenase Type I                                                                                                                   Sigma                                                            10103578001                                                    

  Chemical compound         Dispase Type II                                                                                                                      Sigma                                                            4942078001                                                     

  Chemical compound         L-15                                                                                                                                 Invitrogen                                                       11415--064                                                     

  Chemical compound         Nerve growth factor                                                                                                                  Invitrogen                                                       13290--010                                                     

  Chemical compound         Neurobasal A Medium                                                                                                                  Invitrogen                                                       10888--022                                                     

  Chemical compound         B-27                                                                                                                                 Invitrogen                                                       17504--010                                                     

  Chemical compound         Penicillin-Streptomycin                                                                                                              Invitrogen                                                       15140--122                                                     

  Chemical compound         Fetal calf serum                                                                                                                     Invitrogen                                                       10082--147                                                     

  Chemical compound         Minimal Essential Medium                                                                                                             American Tissue Type Collection                                  EMEM 30--2003                                                  

  Chemical compound         Hank\'s Balanced Salt Solution                                                                                                       Gibco                                                            14170--112                                                     

  Chemical compound         DMEM/F12                                                                                                                             Gibco                                                            11330--032                                                     

  Chemical compound         Tetrodotoxin w/citrate                                                                                                               Abcam                                                            Ab120055                                                       

  Chemical compound         Zymosan                                                                                                                              Sigma                                                            Z4250                                                          

  Software                  Clampex                                                                                                                              Molecular Devices                                                Versions 9.2, 10.3.1.5\                                        <https://www.moleculardevices.com>
                                                                                                                                                                                                                                  RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)   

  Software                  Igor Pro                                                                                                                             Wavemetrics                                                      Version 6.12A\                                                 <https://www.wavemetrics.com>
                                                                                                                                                                                                                                  RRID:[SCR_000325](https://scicrunch.org/resolver/SCR_000325)   

  Software                  DataAccess                                                                                                                           Bruxton Corporation                                                                                                             <http://www.bruxton.com/DataAccess/index.html>

  Software                  GraphPad Prism                                                                                                                       Graph Pad                                                        RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)   Version 5
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cav2.2 recordings {#s4-1}
-----------------

Recordings were made from a cell line stably expressing rat Cav2.2 together with the β3 subunit and the α2δ−1 subunit (line \#201719, [@bib57]) generously provided by Dr. Diane Lipscombe (Brown University, Providence, RI). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin/streptomycin, 25 μg/ml zeocin, 5 μg/ml blasticidin, and 25 μg/ml hygromycin ([@bib57]) under 5% CO~2~ at 37°C. Cell line properties were authenticated by electrophysiology (large voltage-dependent calcium channel currents with kinetic properties expected of this Cav2.2 splice variant, [@bib57]) and pharmacology (inhibition by 1 μM ω-conotoxin GVIA). The cell line tested negative for mycoplasma in tests performed every six months (Lonza MycoAlert PLUS Mycoplasma Detection Kit).

Whole-cell recordings were made at room temperature 24--48 hr after plating cells onto cover slips, using patch pipettes made of borosilicate glass with resistances of 3--4 MΩ when filled with the standard internal solution, consisting of 100 mM CsCl, 1 mM MgCl~2~, 10 mM HEPES, 10 mM BAPTA, 3.6 mM MgATP, 14 mM phosphocreatine, 0.1 mM GTP (lithium salt) and 50 Units/ml creatine phosphokinase, pH adjusted to 7.2 using CsOH. The external solution consisted of 151 mM TEA-Cl, 5 mM BaCl~2~, 1 mM MgCl~2~, 10 mM Glucose, and 10 mM HEPES, pH adjusted to 7.4 with NaOH. A gravity perfusion system connected to a perfusion pencil (AutoMate Scientific) was used to apply compounds to the cell.

Currents were recorded with an Axopatch 200A amplifier, filtered at 5 kHz with a low-pass Bessel filter, and digitized at 10 kHz using a Digidata 1440A data acquisition interface controlled by pClamp10 software (Axon Instruments) and analyzed using Clampfit10, Prizm5, Sigmaplot 10, and Igor Pro 4.0 (Wavemetrics, Lake Oswego, OR). Voltage-activated barium currents were corrected for linear capacitative and leak currents determined using 5 mV hyperpolarizations delivered from the resting potential (usually −70 or −100 mV) and then appropriately scaled and subtracted. Data are given as mean ± SEM.

Mouse SCG recordings {#s4-2}
--------------------

*Cell preparation.* Dissociated neurons from the mouse SCG were prepared by enzymatic dissociation. SCGs were removed from Swiss Webster (CFW) mice (postnatal day 13--16, either sex), cut in half and treated for 20 min at 37°C with 20 U/ml papain (Worthington Biochemical, Lakewood, NJ) and 5 mM dl-cysteine in a Ca^2+^, Mg^2+^--free (CMF) Hank's solution (Gibco, Grand Island, NY) containing (in mM): 136.9 NaCl, 5.4 KCl, 0.34 Na~2~HPO~4~, 0.44 KH~2~PO~4~, 5.55 glucose, 5 HEPES, 0.005% phenol red, pH 7.4. Ganglia were then treated for 20 min at 37°C with 3 mg/ml collagenase (Type I, Sigma-Aldrich, St. Louis, MO) and 4 mg/ml dispase II (Boehringer Mannheim, Indianapolis, IN) in CMF Hank's solution. Cells were dispersed by trituration with a fire-polished glass Pasteur pipette in a solution composed of two media combined in a 2:1 ratio: Leibovitz\'s L-15 medium (Invitrogen, Grand Island, NY) supplemented with 5 mM HEPES, and DMEM/F12 medium (Invitrogen); this solution also had added 100 ng/ml nerve growth factor (NGF) (Invitrogen). Cells were then plated on glass coverslips and were incubated at 37°C (95% O~2~, 5% CO~2~) for 2 hr, after which Neurobasal medium (Invitrogen) containing B-27 supplement (Invitrogen), penicillin and streptomycin (Sigma, St. Louis, MO), and 100 ng/ml NGF was added to the petri dish. Storing the neurons at 4°C inhibited the growth of neurites, so that cells could be voltage clamped with fast settling of the capacity transient, enabling accurate recording of currents on the fast time scale of the action potential.

Recordings were made using electrodes with resistances of 2--3.5 MOhm when filled with an internal solution containing (in mM): 117 mM CsCl, 4.5 mM MgCl~2~, 9 mM EGTA, 9 mM HEPES, 14 mM creatine phosphate (tris salt), 4 mM MgATP, and 0.3 mM GTP (tris salt), 9 mM HEPES, pH adjusted to 7.2 with CsOH. Pipette tips were wrapped with thin strips of parafilm to reduce capacitance. Seals were formed in an external solution containing (in mM): 150 mM TEA-Cl, 5 mM BaCl~2~, 1 mM MgCl~2~, 10 mM HEPES, and 10 mM Glucose, pH adjusted to 7.4 with TEA-OH. After establishing whole-cell recording, cells were lifted off the bottom of the recording chamber and placed in front of an array of quartz flow pipes (250 μm internal diameter, 350 μm external) using the same external solution with addition of 5 μM nimodipine to block L-type calcium channels and 1 mM TTX to block sodium channels. Experiments were done at 37°C, using a feedback controller system (Warner Instruments TC-344C) to control the temperature of the flow pipes, which were glued to a rectangular aluminum rod. Voltage clamp recordings were made using a Multiclamp 700B amplifier (Molecular Devices) with currents and voltages controlled and sampled using a Digidata 1322A interface using pClamp 9.2 software (Molecular Devices). Series resistance was compensated by 40--60%. Current and voltage records were filtered at 5--10 kHz and digitized at 100 kHz. Analysis was performed with Igor Pro (Wavemetrics, Lake Oswego, OR) using DataAccess (Bruxton Software) to import pClamp data. Voltage-activated barium currents were corrected for linear capacitative and leak currents determined using 5 mV hyperpolarizations delivered from the resting potential (usually −70 or −100 mV) and then appropriately scaled and subtracted. Data are given as mean ± SEM.

Nav1.7 recordings {#s4-3}
-----------------

Recordings of Nav1.7 currents were made from a cell line stably expressing human Nav1.7 channels previously made in the lab ([@bib58]). Cells were grown in Minimum Essential Medium (ATCC) containing 10% fetal bovine serum (Sigma), penicillin/streptomycin (Sigma), and 800 μg/ml G418 (Sigma) under 5% CO~2~ at 37°C. Cell line properties were authenticated by electrophysiology (large voltage-dependent sodium channel currents) and pharmacology (inhibition by the Nav1.7-selective inhibitor PF-05089771 with previously-reported kinetics and voltage-dependence; [@bib97]). The cell line tested negative for mycoplasma in tests performed every six months (Lonza MycoAlert PLUS Mycoplasma Detection Kit). For electrophysiological recording, cells were grown on coverslips for 1 to 6 hr after plating.

Whole-cell recordings were obtained using patch pipettes with resistances of 2--3.5 MΩ when filled with the internal solution, consisting of 61 mM CsF, 61 mM CsCl, 9 mM NaCl, 1.8 mM MgCl~2~, 9 m M EGTA, 14 mM creatine phosphate (tris salt), 4 mM MgATP, and 0.3 mM GTP (tris salt), 9 mM HEPES, pH adjusted to 7.2 with CsOH. The shank of the electrode was wrapped with Parafilm to reduce capacitance and allow optimal series resistance compensation without oscillation. After establishing whole-cell recording in Tyrode's solution (155 mM NaCl, 3.5 mM KCl, 1.5 mM CaCl~2~, 1 mM MgCl~2~, 10 mM HEPES, 10 mM glucose, pH adjusted to 7.4 with NaOH) cells were lifted off the bottom of the recording chamber and placed in front of flow pipes. Recordings were made using a base external solution of Tyrode's solution with 10 mM TEACl. Series resistance was compensated by 40--60%. Recordings were made at 37°C using a Multiclamp 700B amplifier and procedures for recording and analysis followed those for SCG neuron experiments.

Mouse DRG recordings {#s4-4}
--------------------

*Cell preparation.* Acutely dissociated DRG neurons were prepared as previously described ([@bib60]; [@bib112]). Briefly, DRG neurons were removed from Swiss Webster mice (CFW) of either sex (P11-P13), treated for 20 min at 37°C with 20 U/ml papain (Worthington Biochemical, Lakewood, NJ) in calcium- and magnesium-free (CMF) Hank's solution (Gibco, Grand Island, NY) containing 137 mM NaCl, 5.36 mM KCl, 0.33 mM Na~2~HPO~4~, 0.44 mM KH~2~PO~4~, 5.55 mM glucose, 4.17 mM NaHCO~3~0.02 mM phenol red, pH 7.40 adjusted with NaOH; 300 \~ 310 mOsm. Ganglia were then treated for 20 min at 37°C with 3 mg/ml collagenase (Type I, Sigma-Aldrich, St. Louis, MO) and 4 mg/ml dispase II (Boehringer Mannheim, Indianapolis, IN) in CMF Hank's solution. Cells were dispersed by trituration with a fire-polished glass Pasteur pipette in a solution composed of two media combined in a 1:1 ratio: Leibovitz\'s L-15 medium (Invitrogen, Grand Island, NY) supplemented with 5 mM HEPES, and DMEM/F12 medium (Invitrogen); this solution also had added 100 ng/ml nerve growth factor (NGF) (Invitrogen). Cells were then plated on glass coverslips and incubated at 37°C (95% O~2~, 5% CO~2~) for 2 hr, after which Neurobasal medium (Invitrogen) containing B-27 supplement (Invitrogen), penicillin and streptomycin (Sigma, St. Louis, MO), and 100 ng/ml NGF was added to the petri dish. Cells were stored at 4°C and used within 48 hr.

Whole cell voltage- and current-clamp recordings were made from DRG neurons using electrodes with resistances of 4--8 MOhm, with tips wrapped by Parafilm. Seals were formed in Tyrode's solution (155 mM NaCl, 3.5 mM KCl, 1.5 mM CaCl~2~, 1 mM MgCl~2~, 10 mM HEPES, 10 mM glucose, pH 7.4 adjusted with NaOH). After establishing whole-cell recording, cell capacitance was nulled and series resistance was partially (70%) compensated. Cells were lifted and placed in front of flow pipes. For current clamp recording, the internal solution consisted of 140 mM K aspartate, 13.5 mM NaCl, 1.6 mM MgCl~2~, 0.09 mM EGTA, 9 mM HEPES, 14 mM creatine phosphate (Tris salt), 4 mM MgATP, 0.3 mM Tris-GTP, pH 7.2 adjusted with KOH and an external Tyrode's solution. Reported membrane potentials are corrected for a liquid junction potential of −10 mV between the internal solution and the Tyrode's solution in which current was zeroed before sealing onto the cell, measured using a flowing 3 M KCl reference electrode as described by [@bib68]. For voltage clamp recordings, the external solution was designed to isolate sodium currents by inhibiting calcium channels and potassium channels and contained 155 mM NaCl, 5 mM TEACl, 3.5 mM KCl, 1.5 mM BaCl~2~, 30 μM CdCl~2~, 1 mM MgCl~2~, 10 mM HEPES, 10 mM glucose, pH 7.4 adjusted with NaOH. Currents through TTX-resistant sodium channels were isolated by including 300 nM TTX in the solution.

Recordings were performed at 37°C using an Axon Instruments Multiclamp 700B Amplifier (Molecular Devices). Procedures for recording and analysis followed those for SCG neuron experiments.

Experiments were done using small diameter DRG neurons (15--30 µm). In voltage clamp experiments, neurons were confirmed to express TRPV1 channels or TTX-resistant sodium currents or both, by testing for currents activated by capsaicin or for sodium currents resistant to 300 nM TTX or for sodium currents with the signature slow inactivation and relatively depolarized steady-state inactivation curves ([@bib12]). Such tests were not always possible in current clamp experiments but these cells had the wide action potentials with shoulders typical of neurons with TTX-resistant sodium channels.

Paw incision model {#s4-5}
------------------

Methods were based on those previously described ([@bib14]; [@bib91]; [@bib25]). Adult (10--12 weeks old) male C57Bl6/J mice (Jackson Laboratories, Bar Harbor, Maine, USA) were housed in groups of 5 for one week prior to use under controlled conditions (lights on 07:00-19:00 hr; humidity 30--50%; temperature 22--23°C) with food and water available ad libitum. Mice were anesthetized with 3--4% isoflurane and surgery performed under maintenance anesthesia with 1.5--2% isoflurane. Following aseptic preparation with alternating washes of the plantar surface of the paw with 10% povidone-iodine solution and 70% alcohol, a 5 mm longitudinal incision was made on the plantar surface of the right paw with a number 11 surgical blade. The underlying muscles were elevated with forceps to confirm that the muscles and tendons were not damaged by the procedure. The skin was closed with two single sutures of 6--0 nylon. Twenty-four hours after the paw incision, mice were gently restrained in a cloth pocket and received a 10 μL bolus injection of either 15 or 30 mM CNCB-2, 30 mM bupivacaine, or vehicle (5% DMSO) in normal saline to the injured paw adjacent to the incision. Each group consisted of 8 mice, based on previous experiments showing sufficient power to detect significance with 95% confidence. Dosing of compounds was performed by an individual different to the person testing for mechanical hypersensitivity, to ensure blinding. The von Frey testing was performed at 1, 4, and 8 hr after drug injection.

Mechanical hypersensitivity was assessed using the von Frey test as previously described ([@bib52]). After animals were habituated to the test cage (7.5 × 7.5×15 cm) with a mesh bottom for 45 min for 2 days, baseline responses were measured using nine von Frey filaments (bending force of 0.04, 0.07, 0.16, 0.4, 0.6, 1, 1.4, 2, and 4 g). Based on the baseline measurement, the mice were assigned to each group so that the baseline mechanical sensitivity among the groups was similar; the test order was randomized. Each filament was applied to the paw three times with 10 s intervals; a withdrawal response was scored if least two of the filament applications elicited flinching or licking of the paw. The up-down method was used to determine the 50% withdrawal threshold following the algorithm of [@bib37].

Intraplantar zymosan injection model {#s4-6}
------------------------------------

Inflammatory pain was induced by zymosan injection ([@bib65]). Either 10 μL of CNCB-2 (30 mM) or vehicle (5% DMSO in normal saline) was injected subcutaneously in the left hind paw of 8-week-old C57Bl6/J female mice (n = 5 each, based on the paw incision results showing sufficient power to detect significance with 95% confidence). One hour later the same paw was injected subcutaneously with 20 μL of zymosan (5 mg/ml in saline; Sigma, Z4250). Four hours after the zymosan injection, the von Frey test was performed by a blinded investigator.

CGRP release from DRG neurons {#s4-7}
-----------------------------

For the CGRP release assay, DRGs were dissected from C57Bl6/J mice into Hank's balanced salt solution, incubated for 90 min at 37°C with 1 mg/ml collagenase A and 2.4 U /ml dispase II (Roche Applied Sciences) in HEPES-buffered saline (Sigma), and then mechanically triturated using glass Pasteur pipettes. DRGs were then centrifuged over a 10% BSA gradient and plated on laminin-coated 96 well plates at approximately 5,000 cells per well. A plate was prepared from each of two mice, each plate with DRGs in 10 wells. DRGs were cultured 48 hr before conducting a CGRP release assay in B27-supplemented neurobasal-A medium plus 50 ng/ml NGF, 2 ng/ml GDNF, 10 µM arabinocytidine and penicillin/streptomycin. The DRG neurons were exposed to 50 mM KCl with vehicle (2 wells of each plate), 50 mM KCl in the presence of 30 µM NNCB-2 (two wells/plate), or 50 mM KCl in the presence of 30 µM CNCB-2 (four wells/plate), with two wells/plate serving as controls with no KCl depolarization (4 mM KCl), for 10 min at 37°C. The supernatants were collected and analyzed using the Rat CGRP Enzyme Immunoassay Kit (Bertin Pharma/Cayman Chemical, \#589001). Plates were read at 405 nm for 0.1 s on a Wallac Victor 1420 Multilabel Counter (Perkin Elmer) and data was analyzed using GraphPad Prism. Data are shown as raw values of absorbance and bars and error bars indicate mean ± SEM.

Allergic airway inflammation {#s4-8}
----------------------------

Allergic airway inflammation was studied in an ovalbumin-based model of type two allergic airway disease ([@bib42]; [@bib95]). On day 0 and day 7, 8-week-old mice (BALB/c, stock number: 001026) were sensitized by a 200 µl i.p. injection of a solution containing 1 mg/ml ovalbumin and 5 mg/ml aluminum hydroxide in phosphate-buffered saline (PBS). On days 14--17 (10:00 am) mice were exposed daily to 6% ovalbumin aerosol for 25 min to produce airway inflammation. On day 18 (near the peak of inflammation in this model), mice were anesthetized using isoflurane and 30 μM CNCB-2 or 100 μM NNCB-2 in PBS was applied intra-nasally as a 50 μL aliquot. On day 21, mice were anesthetized by an intraperitoneal injection of urethane (200 μl i.p., 35%) and a 20G sterile catheter inserted longitudinally into the trachea. To harvest bronchoalveolar lavage fluid, 2 ml of ice cold PBS containing protease inhibitors (Roche) was injected into the lung, harvested and stored on ice. Bronchoalveolar lavage fluid then underwent a 400 g centrifugation (15 min; 4°C), the supernatant was discarded and cells resuspended in 200 µl in FACS buffer (PBS, 2% FCS, EDTA), and incubated with Fc block (0.5 mg/ml, 10 min; BD Biosciences). Cells were then stained with monoclonal antibodies (FITC anti-mouse CD45, BD Biosciences, cat no: 553079, PE anti-mouse Syglec-F, BD Biosciences, cat no: 552126; APC anti-mouse GR-1, eBiosciences, cat no: 17-5931-81; PE-Cy7 anti-mouse CD3e, cat no: 25-0031-81; PerCP anti-mouse F4/80, BioLegend, cat no: 123125; 45 min, 4°C on ice) before data acquisition on a FACS Canto II (BD Biosciences). A leukocyte differential count was determined during flow cytometry analysis of cells expressing the common leukocyte antigen CD45 (BD Pharmigen; cat no: 553079). Specific cell populations were identified as follows: macrophages as F4/80Hi-Ly6gNeg, eosinopohils as F4/80Int-Ly6gLo-SiglecFHi, neutrophils as F4/80Lo-Ly6gHi-SiglecFNeg, and lymphocytes as F4/80Neg-Ly6gNeg-CD3Pos. Total BAL cell counts were performed using a standard hemocytometer, with absolute cell numbers calculated as total BAL cell number multiplied by the percentage of cell subpopulation as determined by FACS ([@bib42]). Data are shown as raw values of cell counts (with outliers included); bars and error bars indicate mean ± SEM.

Chemicals {#s4-9}
---------

NNCB-2 (3-Cyclopentylmethylsulfanyl-2-(3,3-dimethyl-butylamino)-*N*-(4-methoxy-benzyl)-propionamide) and CNCB-2 (\[2-Cyclopentylmethylsulfanyl-1-(4-methoxy-benzylcarbamoyl)-ethyl\]−(3,3-dimethyl-butyl)-dimethyl-ammonium; chloride salt) were designed based on the scaffold described by [@bib84] and custom synthesized (Sundia MediTech Co, Ltd.). Structures were verified by NMR and liquid chromatography mass spectrometry. An early series of exploratory experiments was done with the iodide salt of CNCB-2 (synthesized by Acesys Pharmatech), which gave similar effects as the chloride salt. For in vitro experiments, compounds were prepared as stock solutions of 30 mM in DMSO; stability of CNCB-2 in the DMSO stock solution was verified by liquid chromatography mass spectrometry. For the in vivo paw pad injection experiments where injection of a small volume (10 μL) was necessary to ensure absorption into the tissue, a stock solution of 600 mM CNCB-2 in DMSO was used to enable use as a final concentration of 30 mM in the 10 μL injectant.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The editors and reviewers enjoyed reading about your surprising discoveries with a charged inhibitor of voltage-activated calcium channels. The results in your beautifully revised manuscript convincingly show that adding a permanent positive charge to a previously described uncharged inhibitor of N-type calcium channels results in a molecule that is surprisingly effective at inhibiting both N-type calcium channels and two types of voltage-activated sodium channels (Nav 1.7 and Nav 1.8) in a state-dependent manner from the extracellular side of the membrane. That your new charged inhibitor is more effective than uncharged local anesthetics for treating both incisional and inflammatory pain suggests that it is an exciting new lead molecule to be developed as an analgesic. Although previous studies with charged local anesthetics suggest that they are only effective at inhibiting sodium channels when applied to intracellular solutions, your surprising discovery of a charged inhibitor that is active on the extracellular side of voltage-activated calcium and sodium channels suggests that more effective new local analgesics might be discovered by adding charges to the growing number of neutral Nav 1.7 inhibitors being developed in search of new analgesics.

**Decision letter after peer review:**

Thank you for submitting your article \"A novel cationic N-type calcium channel inhibitor active against neurogenic inflammation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Kenton Jon Swartz as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Diane Lipscombe (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting manuscript on the actions of positively charged and neutral small molecule inhibitors of N-type CaV channels. These compounds were synthesized based on previously described amino acid based CaV channel inhibitors, with the goal of extending the groups work on charges local anesthetic blockers of NaV channels that only block from the inside but can enter nociceptors through TRPV1 channels. In this case the charged inhibitor works from both sides, so the authors characterized the concentration and state-dependence of inhibition, showing that they can bind to closed channels but that they inhibit better at depolarized holding voltages. They also found that they are effective inhibitors of CGRP release and neurogenic pain. This is a very nice study, and with great potential to facilitate development of novel analgesics. The following are suggestions for improving the manuscript in revision.

Essential revisions:

1\) We feel that it is essential to get more information about whether this compound is selective for Cav2.2 specifically or even calcium channels in general. All the characterization is done on HEK cells stably expressing CaV2.2. What about other channels? What effect does this compound have on the electrical properties of primary sensory neurons? Does it block the endogenous Cav2.2 current? Does it have effects on other ion channels expressed in sensory neurons? What\'s the IC50 in neurons? Feel free to contact the BRE directly if you need to discuss the scope of any of these suggested experiments, as *eLife* does not wish to ask for very extensive new experiments!

2\) The effect of NNCB-2 on high K mediated CGRP release is relatively small and this seems somewhat inconsistent with the effect of NNCB-2 on CaV2.2 currents especially under steady depolarization conditions. Based on Figure 1, 30 μm NNCB-2 should inhibit most CaV2.2 channels. Do the authors have comparable experiments with w-CgTxGIVA or are there reports in the literature to reference? It\'s possible that other CaV channels are contributing to CGRP release from these neurons.

3\) Can the authors provide any information about the mechanism of inhibition or why the charged compound works from both sides of the membrane. Our guess is that these inhibitors are not pore blockers but are interacting with the channel within the membrane. Maybe even the voltage sensors. The ion selectivity filter resides in the external pore in all these channels and would likely be a large barrier to access to the internal pore. It would be great if the authors could provide more mechanistic information, but even if they cannot at this time, it would be good to discuss the potential mechanisms and we would suggest replacing \'blocker\' with \'inhibitor\' throughout to avoid mechanistic inference.

4\) A related point is whether the external solution was flowing during the internal application experiment. If not, perhaps the inhibitor can partition into the membrane and concentrate within the external leaflet where its site of action may reside?

5\) How was chemical composition validated? Mass spec? 1D NMR? Some basic information should be provided even in cases where a company was contracted to do the synthesis.

Suggested revisions:

1\) The in vivo results while intriguing are only a single assay. What about nocifensive responses (since this is how they introduce their study)? Can it locally injected into the skin (as the authors have done previously with non-permeant sodium channel blockers)? Does the compound attenuate acute heat or mechanical responses? How about under inflammatory or injury conditions?
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Author response

> Essential revisions:
>
> 1\) We feel that it is essential to get more information about whether this compound is selective for Cav2.2 specifically or even calcium channels in general. All the characterization is done on HEK cells stably expressing CaV2.2. What about other channels? What effect does this compound have on the electrical properties of primary sensory neurons? Does it block the endogenous Cav2.2 current? Does it have effects on other ion channels expressed in sensory neurons? What\'s the IC50 in neurons? Feel free to contact the BRE directly if you need to discuss the scope of any of these suggested experiments, as eLife does not wish to ask for very extensive new experiments!

To address this point, we began by testing the compound on native N-type calcium channels in mouse sympathetic ganglion neurons. We found that inhibition of native N-type calcium channels is similarly potent as for the cloned channels in HEK cells. This new data is in Figure 4.

In parallel, we also did tests of the compound on excitability of nociceptive primary sensory neurons, as was also suggested. We were very surprised to find that the compound inhibits firing of action potentials very effectively, quite unexpected if it were acting only on calcium channels. This new data is in Figure 7. We also did voltage clamp experiments on sodium channels in nociceptive DRG neurons as well as on Nav1.7 sodium channels expressed in HEK cells, and found that the charged compound inhibits both Nav1.7 and Nav1.8 channels very potently, producing use-dependent inhibition of Nav.7 channels 10 times more potently than lidocaine and three times more potently than bupivacaine, the most potent local anesthetic. This new data is in Figures 5, 6, and 8.

> 2\) The effect of NNCB-2 on high K mediated CGRP release is relatively small and this seems somewhat inconsistent with the effect of NNCB-2 on CaV2.2 currents especially under steady depolarization conditions. Based on Figure 1, 30 μm NNCB-2 should inhibit most CaV2.2 channels. Do the authors have comparable experiments with w-CgTxGIVA or are there reports in the literature to reference? It\'s possible that other CaV channels are contributing to CGRP release from these neurons.

This is a good point. We have added references to reports in the literature on this point, suggesting that a mixture of calcium channels contribute to peptide release in this system. We have also modified the discussion of these experiments. Because it is likely that the calcium entry triggering CGRP release is through multiple calcium channels, we have removed the implication that the greater efficacy of CNCB-2 in this system is necessarily due to greater efficacy in inhibiting N-type calcium channels. We would have to do many more experiments studying dose-response of both CNCB-2 and NNCB-2 on multiple cloned calcium channels to clarify this. We are mainly interested in the efficacy of CNCB-2, not NNCB-2, as a possible clinical agent, so we have focused on its effects, which are stronger than those of NNCB-2 in both CGRP release and lung inflammation. At this point, the unexpectedly powerful effects of CNCB-2 on sodium channels seemed of more interest to study in detail than a study of effects on other calcium channels, although we plan to do such a study in the future.

> 3\) Can the authors provide any information about the mechanism of inhibition or why the charged compound works from both sides of the membrane. Our guess is that these inhibitors are not pore blockers but are interacting with the channel within the membrane. Maybe even the voltage sensors. The ion selectivity filter resides in the external pore in all these channels and would likely be a large barrier to access to the internal pore. It would be great if the authors could provide more mechanistic information, but even if they cannot at this time, it would be good to discuss the potential mechanisms and we would suggest replacing \'blocker\' with \'inhibitor\' throughout to avoid mechanistic inference.

This is an important point --thanks. We agree that interaction with the channel within the membrane to affect gating is a more plausible mechanism than pore block, especially given the compound's ability to inhibit both calcium and sodium channels and its voltage-dependent and use-dependent properties for inhibition of both channels. We have added a discussion of this point and have replaced "blocker" with "inhibitor" throughout.

> 4\) A related point is whether the external solution was flowing during the internal application experiment. If not, perhaps the inhibitor can partition into the membrane and concentrate within the external leaflet where its site of action may reside?

We have added a discussion discussing this possibility, along with the more general caveat about the difficulty of accurately defining the time-course of exposure of the cell membrane to compounds applied in the pipette solution in whole-cell recording, which we have previously explored in comparing lidocaine and QX-314 (Jo and Bean, 2014). Application with inside-out patches would be better for defining the kinetics and concentration-dependence of internally applied CNCB-2 but would be technically very challenging, especially for calcium channels where channel activity runs down quickly in inside-out patches.

> 5\) How was chemical composition validated? Mass spec? 1D NMR? Some basic information should be provided even in cases where a company was contracted to do the synthesis.

Structures were verified by both NMR and liquid chromatography mass spectrometry, with the data furnished by the company who did the synthesis and reviewed by co-author Jinbo Lee, a medicinal chemist. We have added this information to the Materials and methods. We also independently performed liquid chromatography mass spectrometry of stock solutions of CNCB-2 in DMSO to verify stability of the compound in solution (performed by co-author Laurel Heckman, trained as an organic chemist).

> Suggested revisions:
>
> 1\) The in vivo results while intriguing are only a single assay. What about nocifensive responses (since this is how they introduce their study)? Can it locally injected into the skin (as the authors have done previously with non-permeant sodium channel blockers)? Does the compound attenuate acute heat or mechanical responses? How about under inflammatory or injury conditions?

This is a great suggestion that became even more important when we found that the compound effectively inhibits sodium channels as well as calcium channels. We originally assumed that the compound was only a calcium channel inhibitor and would only be effective in reducing inflammation associated with neuropeptide release. We choose the mouse asthma model because of previous evidence for a strong involvement of neuropeptides. We have now done a new series of experiments on two different pain models, nocifensive behavior following paw incision and a zymosan-induced inflammation model. We find very effective and long-lasting analgesia in both models, with effects of a single injection lasting at least 8 hours in the paw incision model. CNCB2 is far more long-lasting than bupivacaine in this model. The new data is presented in Figure 9.

[^1]: These authors contributed equally to this work.
